抗血管靶向药联合免疫检查点抑制剂在晚期非小细胞肺癌中的研究进展

靳 云泽
河北医科大学

摘要

在中国,肺癌仍是夺取癌症病人生命的"第一杀手",其中非小细胞肺癌(non-smallcelllungcancer,NSCLC)又是最为多见的亚型,且大部分患者确诊时已经无法通过手术根治｡尤其对于EGFR阴性人群,传统的含铂双药化疗方案不仅毒性大,且对于预后的改善并不令人满意｡免疫逃逸和血管生成是恶性肿瘤的两个重要特征,而免疫治疗和抗血管生成治疗分别通过激活机体的免疫应答功能和阻断肿瘤新生血管生成,从而发挥抗肿瘤效应｡且大量研究表明,这两者之间具有潜在的协同效应｡本文将就抗血管成药物联合PD-1/PD-L1抑制剂在晚期NSCLC中的临床应用进行综述｡

关键词

晚期非小细胞肺癌;抗血管靶向药;免疫检查点抑制剂

参考

[1]SiegelRL,MillerKD,FuchsHE,etal.Cancerstatistics,2022[J].CACancerJClin,2022,72(1):7-33.[2]WuFY,WangL,ZhouCC.LungcancerinChina:currentandprospect[J].CurrOpinOncol,2021,33(1):40-46.[3]SungH,FerlayJ,SiegelRL,etal.GlobalCancerStatistics2020:GLOBOCANEstimatesofIncidenceandMortalityWorldwidefor36Cancersin185Countries[J].CA:acancerjournalforclinicians,2021,71(3):209-49.[4]杨佳,张楠,杜振华,等.2013-2018年山东省肥城市主要恶性肿瘤的早死概率和疾病负担分析[J].中国肿瘤,2020(9):682-688.[5]ZengQ,VogtmannE,JiaMM,etal.TobaccosmokingandtrendsinhistologicalsubtypesoffemalelungcancerattheCancerHospitaloftheChineseAcademyofMedicalSciencesover13years[J].ThoracCancer,2019,10(8):1717-1724.[6]UngMH,MacKenzieTA,OnegaTL,etal.Statinsassociatewithimprovedmortalityamongpatientswithcertainhistologicalsubtypesoflungcancer[J].LungCancer,2018,126:89-96.[7]GriesingerF,KorolEE,KayaniyilS,etal.Efficacyandsafetyoffirst-linecarboplatin-versuscisplatin-basedchemotherapyfornon-smallcelllungcancer:ameta-analysis[J].LungCancer,2019,135:196-204.[8]TopalianSL,HodiFS,BrahmerJR,etal.Five-yearsurvivalandcorrelatesamongpatientswithadvancedmelanoma,renalcellcarcinoma,ornon-smallcelllungcancertreatedwithnivolumab[J].JAMAOncol,2019,5(10):1411-1420.[9]RemonJ,PassigliaF,AhnMJ,etal.Immunecheckpointinhibitorsinthoracicmalignancies:ReviewoftheexistingevidencebyanIASLCexpertpanelandrecommendations.JThoracOncol,2020,15(6):914-947.doi:10.1016/j.jtho.2020.03.006[10]JinhuaLong,ZuquanHu,HuiXue,etal.VascularEndothelialGrowthFactor(VEGF)ImpairstheMotilityandImmuneFunctionofHumanMatureDendriticCellsthroughtheVEGFReceptor2-RhoA-cofilin1Pathway[J].CancerScience,2019:doi:10.1111/cas.14091.[11]VoronT,ColussiO,MarcheteauE,etal.VEGF-AModulatesExpressionofInhibitoryCheckpointsonCD8+TCellsinTumors[J].JournalofExperimentalMedicine,2015,212(2):139.[12]LaetitiaM,MagaliT,EricT,etal.ControloftheAdaptiveImmuneResponsebyTumorVasculature[J].FrontiersinOncology,2014(4):61.[13]FolkmanJ.Tumorangiogenesis:therapeuticimplications.NEnglJMed,1971,285(21):1182-1186.doi:10.1056/nejm197111182852108[14]chitoL,SemenzaGL.Hypoxia-InducibleFactors:MasterRegulatorsofCancerProgression[J].TrendsCancer,2016,2(12):758-770.[15]ViallardC,LarriveeB.Tumorangiogenesisandvascularnormalization:alternativetherapeutictargets[J].Angiogenesis,2017,20(4):409-426.[16]TsaiHF,HsuPN.Cancerimmunotherapybytargetingimmunecheckpoints:mechanismofTcelldysfunctionincancerimmunityandnewtherapeutictargets.JBiomedSci,2017,24(1):35.doi:10.1186/s12929-017-0341-0[17]ScientificBackground:DiscoveryofCancerTherapybyInhibitionofNegativeImmuneRegulation[EB/OL].(2018-10-01)[2021-03-25].https://www.nobelprize.org/prizes/medicine/2018/advanced-information/.[18]ErfaniN,MehrabadiSM,GhayumiMA,etal.IncreaseofregulatoryTcellsinmetastaticstageandCTLA-4overexpressioninlymphocytesofpatientswithnon-smallcelllungcancer(NSCLC).LungCancer,2012,77(2):306-311.doi:10.1016/j.lungcan.2012.04.011[19]YiM,JiaoD,XuH,etal.BiomarkersforpredictingefficacyofPD-1/PD-L1inhibitors.MolCancer,2018,17(1):129.doi:10.1186/s12943-018-0864-3[20]WakamatsuE,MathisD,BenoistC.ConvergentanddivergenteffectsofcostimulatorymoleculesinconventionalandregulatoryCD4+Tcells.ProcNatlAcadSciUSA,2013,110(3):1023-1028.doi:10.1073/pnas.1220688110[21]Marin-AcevedoJA,SoyanoAE,DholariaB,etal.Cancerimmunotherapybeyondimmunecheckpointinhibitors.JHematolOncol,2018,11(1):8.doi:10.1186/s13045-017-0552-6[22]QIANXiangyun,GEWei.Recentadvancesintherelationshipbetweenresistancetotumoranti-angiogenicstrategiesandtumormicroenvironment[J].ChinaMedHerald,2016,13(18):33-36.(inChinese)钱祥云,戈伟.抗血管生成治疗耐药与肿瘤微环境关系的研究进展[J]中国医药导报,2016,13(18)33-6[23]CarmelietP,JainRK.Angiogenesisincancerandotherdiseases.Nature,2000,407(6801):249-257.doi:10.1038/35025220[24]GriffioenAW.Anti-angiogenesis:makingthetumorvulnerabletotheimmunesystem.CancerImmunolImmunother,2008,57(10):1553-1558.doi:10.1007/s00262-008-0524-3[25]FacciabeneA,MotzGT,CoukosG.T-regulatorycells:keyplayersintumorimmuneescapeandangiogenesis.CancerRes,2012,72(9):2162-2171.doi:10.1158/0008-5472.Can-11-3687[26]HuberV,CamisaschiC,BerziA,etal.Canceracidity:anultimatefrontieroftumorimmuneescapeandanoveltargetofimmunomodulation.SeminCancerBiol,2017,43:74-89.doi:10.1016/j.semcancer.2017.03.001[27]WangJ,LiD,CangH,etal.Crosstalkbetweencancerandimmunecells:roleoftumor-associatedmacrophagesinthetumormicroenvironment.CancerMed,2019,8(10):4709-4721.doi:10.1002/cam4.2327[28]PircherA,WolfD,HeidenreichA,etal.Synergiesoftargetingtumorangiogenesisandimmunecheckpointsinnon-smallcelllungcancerandrenalcellcancer:frombasicconceptstoclinicalreality.IntJMolSci,2017,18(11):2291.doi:10.3390/ijms18112291[29]ViallardC,LarrivéeB.Tumorangiogenesisandvascularnormalization:alternativetherapeutictargets.Angiogenesis,2017,20(4):409-426.doi:10.1007/s10456-017-9562-9[30]HuangY,GoelS,DudaDG,etal.Vascularnormalizationasanemergingstrategytoenhancecancerimmunotherapy.CancerRes,2013,73(10):2943-2948.doi:10.1158/0008-5472.Can-12-4354[31]HuangY,GoelS,DudaDG,etal.Vascularnormalizationasanemergingstrategytoenhancecancerimmunotherapy.CancerRes,2013,73(10):2943-2948.doi:10.1158/0008-5472.Can-12-4354[32]HuangY,KimBYS,ChanCK,etal.Improvingimmune-vascularcrosstalkforcancerimmunotherapy.NatRevImmunol,2018,18(3):195-203.doi:10.1038/nri.2017.145[33]HuangY,YuanJ,RighiE,etal.Vascularnormalizingdosesofantiangiogenictreatmentreprogramtheimmunosuppressivetumormicroenvironmentandenhanceimmunotherapy.ProcNatlAcadSciUSA,2012,109(43):17561-17566.doi:10.1073/pnas.1215397109[34]FacciabeneA,MotzGT,CoukosG.T-regulatorycells:keyplayersintumorimmuneescapeandangiogenesis.CancerRes,2012,72(9):[35]HuangY,GoelS,DudaDG,etal.Vascularnormalizationasanemergingstrategytoenhancecancerimmunotherapy.CancerRes,2013,73(10):2943-2948.doi:10.1158/0008-5472.Can-12-4354[36]HuberV,CamisaschiC,BerziA,etal.Canceracidity:anultimatefrontieroftumorimmuneescapeandanoveltargetofimmunomodulation.SeminCancerBiol,2017,43:74-89.doi:10.1016/j.semcancer.2017.03.001[37]WangJ,LiD,CangH,etal.Crosstalkbetweencancerandimmunecells:roleoftumor-associatedmacrophagesinthetumormicroenvironment.CancerMed,2019,8(10):4709-4721.doi:10.1002/cam4.2327[38]PircherA,WolfD,HeidenreichA,etal.Synergiesoftargetingtumorangiogenesisandimmunecheckpointsinnon-smallcelllungcancerandrenalcellcancer:frombasicconceptstoclinicalreality.IntJMolSci,2017,18(11):2291.doi:10.3390/ijms18112291[39]ViallardC,LarrivéeB.Tumorangiogenesisandvascularnormalization:alternativetherapeutictargets.Angiogenesis,2017,20(4):409-426.doi:10.1007/s10456-017-9562-9[40]LongJ,HuZ,XueH,etal.Vascularendothelialgrowthfactor(VEGF)impairsthemotilityandimmunefunctionofhumanmaturedendriticcellsthroughtheVEGFreceptor2-RhoA-cofilin1pathway.CancerSci,2019,110(8):2357-2367.doi:10.1111/cas.14091[41]PalazonA,TyrakisPA,MaciasD,etal.AnHIF-1α/VEGF-AaxisincytotoxicTcellsregulatestumorprogression.CancerCell,2017,32(5):669-683.e5.doi:10.1016/j.ccell.2017.10.003[42]VoronT,ColussiO,MarcheteauE,etal.VEGF-AmodulatesexpressionofinhibitorycheckpointsonCD8+Tcellsintumors.JExpMed,2015,212(2):139-148.doi:10.1084/jem.20140559[43]TianL,GoldsteinA,WangH,etal.Mutualregulationoftumourvesselnormalizationandimmunostimulatoryreprogramming[J].Nature,2017,544(7649):250-254.[44]GeorganakiM,vanHoorenL,DimbergA.Vasculartargetingtoincreasetheefficiencyofimmunecheckpointblockadeincancer[J].FrontImmunol2018,9:3081.[45]DiTacchioM,MacasJ,WeissenbergerJ,etal.Tumorvesselnormalizationimmunostimulatoryreprogramming,andimprovedsurvivalinglioblastomawithcombinedinhibitionofPD-1,angiopoietin-2,andVEGF[J].CancerImmunolRes,2019,7(12):1910-1927.[46]TianL,GoldsteinA,WangH,etal.Mutualregulationoftumourvesselnormalizationandimmunostimulatoryreprogramming.Nature,2017,544(7649):250-254.doi:10.1038/nature21724[47]KammertoensT,FrieseC,ArinaA,etal.Tumourischaemiabyinterferon-γresemblesphysiologicalbloodvesselregression.Nature,2017,545(7652):98-102.doi:10.1038/nature22311[48]Lopes-CoelhoF,MartinsF,PereiraSA,etal.Anti-angiogenictherapy:currentchallengesandfutureperspectives[J].IntJMolSci,2021,22(7):3765.[49]MartinR,MokTonySK,MakotoN,etal.Atezolizumabplusbevacizumabandchemotherapyinnon-small-celllungcancer(IMpower150):keysubgroupanalysesofpatientswithEGFRmutationsorbaselinelivermetastasesinarandomised,open-labelphase3trial.LancetRespirMed,2019,7(5):387-401.doi:10.1016/S2213-2600(19)30084-0[50]ReckM,MokTSK,NishioM,etal.Atezolizumabplusbevacizumabandchemotherapyinnon-small-celllungcancer(IMpower150):keysubgroupanalysesofpatientswithEGFRmutationsorbaselinelivermetastasesinarandomised,open-labelphase3trial.LancetRespirMed,2019,7(5):387-401.doi:10.1016/S2213-2600(19)30084-0[51]SocinskiMA,JotteRM,FedericoC,etal.AtezolizumabforFirst-LineTreatmentofMetastaticNonsquamousNSCLC[J].NewEnglandJournalofMedicine,2018,378:doi:NEJMoa1716948.[52]SocinskiMA,JotteRM,CappuzzoF,etal.OverallSurvival(OS)AnalysisofIMpower150,aRandomizedPh3StudyofAtezolizumab(Atezo)+Chemotherapy(Chemo)±Bevacizumab(Bev)vsChemo+Bevin1LNonsquamous(NSQ)NSCLC[J].JournalofClinicalOncology,2018,36(15_suppl):9002-9002.[53]HerbstRS,ChauI,PetrylakDP,etal.Activityoframucirumab(R)withpembrolizumab(P)byPD-L1expressioninadvancedsolidtumors:phase1a/bstudyinlaterlinesoftherapy[J].JClinOncol,2018,36(15_Suppl):3059.[54]DINGLY,LIUKJ,JIANGZL,etal.TheEfficacyandSafetyofPemetrexedPlusBevacizumabinPreviouslyTreatedPatientswithAdvancedNon-squamousNon-smallCelllungCancer(ns-NSCLC)[J].TumourBiol,2015,36(4):2491-2499.[55]GadgeelSM,StevensonJP,LangerCJ,etal.Pembrolizumabandplatinum-basedchemotherapyasfirst-linetherapyforadvancednon-small-celllungcancer:phase1cohortsfromthekeynote-021study[J].LungCancer,2018,125:273-281.[56]ZhanshengJIANG,ZhanyuPAN,XiubaoREN.ProgressofPD-1/PD-L1InhibitorsinNon-smallCellLungCancer[J].ChineseJournalofLungCancer,2017,20(2):138-142.[57]HosseinBorghaei,CoreyJLanger,ShirishGadgeel,etal.24-MonthOverallSurvivalFromKEYNOTE-021CohortG:PemetrexedandCarboplatinwithorwithoutPembrolizumabAsFirst-LineTherapyforAdvancedNonsquamousNon-Small-CellLungCancer[J].JournalofThoracicOncology,2018:doi:10.1016/j.jtho.2018.08.004.[58]HerbstRS,ChauI,PetrylakDP,etal.Activityoframucirumab(R)withpembrolizumab(P)byPD-L1expressioninadvancedsolidtumors:phase1a/bstudyinlaterlinesoftherapy[J].JClinOncol,2018,36(15_Suppl):3059.[59]TaylorMH,LeeCH,MakkerV,etal.PhaseIB/IItrialoflenvatinibpluspembrolizumabinpatientswithadvancedrenalcellcarcinoma,endometrialcancer,andotherselectedadvancedsolidtumors[J].JClinOncol,2020,38(11):1154-1163.[60]NishioM,PeledN,ZerA,etal.1313PphaseIIILEAP-006safetyrun-in(part1):1Lpembrolizumab(pembro)+chemotherapy(chemo)withlenvatinib(len)formetastaticNSCLC.AnnOncol,2020,31:S848-S849.doi:10.1016/j.annonc.2020.08.1627[61]YangJCH,LuftA,delaMoraJiménezE,etal.120OPembrolizumab(Pembro)withorwithoutlenvatinib(Lenvainfirst-linemetastaticNSCLCwithPD-L1TPS≥1%(LEAP007):aphaseIII,randomized,double-blindstudy[J].AnnOncol,2021,32:S1429-S1430.[62]ChuTQ,ZhongRB,ZhongH,etal.Phase1bstudyofsintilimabplusanlotinibasfirst-linetherapyinpatientswithadvancedNSCLC[J].JThoracOncol,2021,16(4):643-652.[63]ZhouC,GaoG,WangYN,etal.EfficacyofPD-1monoclonalantibodySHR-1210plusapatinibinpatientswithadvancednonsquamousNSCLCwithwild‐typeEGFRandALK.JClinOncol,2019,37(15_suppl):9112.doi:10.1200/JCO.2019.37.15_suppl.9112[64]GaoG,WangY,RenS,etal.1267PEfficacyofcamrelizumab(SHR-1210)plusapatinibassecond-linetreatmentforadvancedsquamousNSCLC.AnnOncol,2020,31:S819.doi:10.1016/j.annonc.2020.08.1581